What is the role of the R-hyper-CVAD chemotherapy regimen in the treatment of relapsed mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

This therapy is currently being tested in patients with relapsed MCL in whom fludarabine or CHOP failed, but the results are not yet available. However, based on the frontline data, this is an acceptable option in patients with relapse. Future combinations of R-hyper-CVAD with other biologicals or new agents are potentially promising options.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!